Novel Antitumor(新型抗肿瘤)研究综述
Novel Antitumor 新型抗肿瘤 - A microwave-assisted, chemoselective synthesis of novel antitumor and antimicrobial (3E)-5-hydroxy-1-isopropyl-3-[(5-methyl-2-thienyl)methylene]-5-phenylpyrrolidin-2-one has been achieved via the solvent-free one-pot reaction of (3E)-3-[(5-methyl-2-thienyl)methylene]-5-phenylfuran-2(3H)-one with isopropylamine. [1] These findings indicate that TRPC6 downregulation might be involved in melatonin's inhibitory effects on Ca2+ influx and the maintenance of cancer hallmarks, and point toward a novel antitumoral mechanism of melatonin in TNBC cells. [2] So far, the molecular basis of the drugs mechanism has focused primarily on DNA damage, but recently the novel antitumoral strategies highlighted the cell membranes as a relevant site of the drug’s multitarget reactivity towards the unsaturated lipids. [3] The focus of this Special Issue of Pharmaceuticals is on the design, synthesis, and molecular mechanism of action of novel antitumor, drugs with a special emphasis on the relationship between the chemical structure and the biological activity of the molecules. [4] Whereas it appears that the use of old and new PET radiopharmaceuticals can advance the non-invasive assessment of treatment response in GBM, the optimal match of biomarker–probe pairs although highly needed is still being sought in particular with the active development of new highly specific treatments characterized by novel antitumoral targeting strategies. [5]通过微波辅助化学选择性合成新型抗肿瘤和抗菌 (3E)-5-hydroxy-1-isopropyl-3-[(5-methyl-2-thienyl)methylene]-5-phenylpyrrolidin-2-one (3E)-3-[(5-甲基-2-噻吩基)亚甲基]-5-苯基呋喃-2(3H)-one与异丙胺的无溶剂一锅法反应。 [1] 这些发现表明，TRPC6 下调可能与褪黑激素对 Ca2+ 流入的抑制作用和癌症标志的维持有关，并指出褪黑激素在 TNBC 细胞中的一种新的抗肿瘤机制。 [2] 到目前为止，药物机制的分子基础主要集中在 DNA 损伤上，但最近新的抗肿瘤策略强调细胞膜是药物对不饱和脂质的多靶点反应的相关位点。 [3] 本期药物特刊的重点是新型抗肿瘤药物的设计、合成和分子作用机制，特别强调分子的化学结构和生物活性之间的关系。 [4] 尽管新旧 PET 放射性药物的使用似乎可以促进对 GBM 治疗反应的无创评估，但仍在寻求生物标志物-探针对的最佳匹配，尽管非常需要，特别是随着新的高度特异性的积极开发以新型抗肿瘤靶向策略为特征的治疗方法。 [5]
Develop Novel Antitumor
In an attempt to develop novel antitumor candidates, a series of coumarin sulfonamides and amides derivatives were designed and synthetized. [1] Due to its interesting biological profile, (S)-1 represents a lead compound to develop novel antitumor agents for breast cancer treatment. [2] This paper focuses on the thermochemical behavior of two derivatives of 1,2,4-triazole which is often considered as a potential synthetic platform to develop novel antitumor or antimicrobial drugs, i. [3]为了开发新的抗肿瘤候选物，设计和合成了一系列香豆素磺酰胺和酰胺衍生物。 [1] 由于其有趣的生物学特征，(S)-1 是开发用于治疗乳腺癌的新型抗肿瘤药物的先导化合物。 [2] 本文重点研究 1,2,4-三唑的两种衍生物的热化学行为，这通常被认为是开发新型抗肿瘤或抗菌药物的潜在合成平台，即。 [3]
Potential Novel Antitumor
Conclusion These results indicate that at least for primary gastric cancer, statins and avasimibe are promising candidates as potential novel antitumor drugs that target the metabolism of isoprenoids and cholesterol of gastric tumors. [1] Recently, drugs belonging to the biguanide class (including metformin) were reported to selectively inhibit CLIC1 activity in CSCs, impairing their viability and invasiveness, but sparing normal stem cells, thus representing potential novel antitumor drugs with a safe toxicological profile. [2]结论这些结果表明，至少对于原发性胃癌，他汀类药物和阿伐西贝作为靶向胃肿瘤异戊二烯和胆固醇代谢的潜在新型抗肿瘤药物是有希望的候选药物。 [1] 最近，据报道属于双胍类的药物（包括二甲双胍）选择性地抑制 CSCs 中的 CLIC1 活性，削弱其活力和侵袭性，但不影响正常干细胞，因此代表了具有安全毒理学特征的潜在新型抗肿瘤药物。 [2]
Developing Novel Antitumor 开发新型抗肿瘤药物
Thus, modification of the diene moiety of Oligomycin A is a promising strategy for developing novel antitumor agents based on its scaffold. [1] These results indicated that compound 8f may be used as a valuable skeleton structure for developing novel antitumor agents. [2]因此，寡霉素 A 的二烯部分的修饰是开发基于其支架的新型抗肿瘤剂的有前景的策略。 [1] 这些结果表明化合物8f可作为一种有价值的骨架结构用于开发新型抗肿瘤药物。 [2]
Discover Novel Antitumor 发现新型抗肿瘤
It is necessary to discover novel antitumor agents for the treatment of esophageal cancers because of its poor prognosis. [1] It is necessary to discover novel antitumor agents for the treatment of esophageal cancers because of its poor prognosis. [2]由于食管癌预后不良，有必要发现新的抗肿瘤药物治疗食管癌。 [1] 由于食管癌预后不良，有必要发现新的抗肿瘤药物治疗食管癌。 [2]
novel antitumor agent 新型抗肿瘤剂
The data obtained suggest that OVN‑002 might be considered as a novel antitumor agent. [1] Regorafenib and TAS-102 are novel antitumor agents for patients with refractory mCRC. [2] The present study highlighted the importance of A-azepano-ring in the triterpenic core for the development of novel antitumor agents, and a future aim to increase the selectivity profile will thus lie in the area of modifications of azepano-triterpenic acids at their carboxyl group. [3] Thus, modification of the diene moiety of Oligomycin A is a promising strategy for developing novel antitumor agents based on its scaffold. [4] These results indicated that compound 8f may be used as a valuable skeleton structure for developing novel antitumor agents. [5] It represents as a promising lead for further optimization and a template for development of novel antitumor agents. [6] Thus, compound MSN54 is a promising candidate for the development of novel antitumor agents. [7] With the aim to discover potent and novel antitumor agents, a series of thiourea compounds bearing 3-(4-methoxyphenyl)azetidine moiety were designed according to the essential pharmacophoric features of the reported VEGFR-2 inhibitors and synthesized. [8] It is necessary to discover novel antitumor agents for the treatment of esophageal cancers because of its poor prognosis. [9] In this review, we demonstrate the efficacy and safety of H2 as a novel antitumor agent and show that its mechanisms may not only involve the direct scavenging of ·OH, but also other indirect biological defense mechanisms via the regulation of gene expression. [10] Therefore, it is supposed that HO-1 inhibitors could become a novel antitumor agent. [11] Drug development of novel antitumor agents is conventionally divided by phase and cancer indication. [12] It is necessary to discover novel antitumor agents for the treatment of esophageal cancers because of its poor prognosis. [13] Thus, the novel unsaturated pyrrolidone p53-MDM2 inhibitors could be developed as novel antitumor agents. [14] Romidepsin (FK228) and vorinostat (SAHA) are histone deacetylase inhibitors (HDACi) approved by the Food and Drug Administration as novel antitumor agents. [15] A series of O-substituted analogs of the C-ring-truncated scaffold of deguelin designed as heat shock protein 90 (HSP90) C-terminal inhibitors were investigated as novel antitumor agents against human epidermal growth factor receptor 2 (HER2)-positive breast cancer. [16] The purpose of this study was to explore the possibilities of using MRS5698 as a novel antitumor agent through experiments on Ishikawa and HEC-1A cells. [17] Although the introduction of novel antitumor agents, such as dinutuximab, isotretinoin, irinotecan, or I-131- metaiodobenzylguanidine, has increased survival rates, the situation in high-risk NB remains dismal. [18] Conclusion Derivative 10 is an novel antitumor agent with potential for further clinical applications to treat gastric cancer. [19] Due to its interesting biological profile, (S)-1 represents a lead compound to develop novel antitumor agents for breast cancer treatment. [20] Our results also suggest that Rhein has a promising potential to be used as a novel antitumor agent for the treatment of NSCLC. [21] These results indicated that EGLP showed stronger antitumor activity with lower toxic effects and had the potential to be a novel antitumor agent. [22] We also suggest that CGRP antibodies may also be used as novel antitumor agents by suppressing tumor-associated angiogenesis. [23] Thus, MnSbW-bpp, as a new compound, possesses the potent inhibition of cancer cells, which indicates that the MnSbW-bpp has potential merit for the further evaluation of a novel antitumor agent. [24] Overall, the current study provides a potential new approach for the discovery of a novel antitumor agent against HCC. [25] Research efforts are focusing on deciphering the distinct molecular mechanisms underlying drug resistance, which should prompt the development of novel antitumor agents that surmount such chemoresistance modalities. [26] Here we show the efficacy and biological mechanism of a novel antitumor agent, NCT compound. [27] Organometallic rhenium complexes have recently been considered in the development of novel antitumor agents due to their suitable properties. [28] Oncolytic viruses are novel antitumor agents with the ability to selectively replicate and lyse tumor cells while sparing healthy tissue. [29] To find novel antitumor agents, a series of 1H-benzofuro[3,2-c]pyrazole derivatives 4a-e were designed and synthesized. [30] Results indicated that as a novel antitumor agent, 1G exhibited acceptable pharmacokinetic properties for further in vivo pharmacologic evaluation. [31] Chemotherapy resistance is one of the most common causes of death among patients with ovarian cancer, and identifying novel antitumor agents is a priority. [32]获得的数据表明 OVN-002 可能被认为是一种新型抗肿瘤剂。 [1] Regorafenib 和 TAS-102 是用于难治性 mCRC 患者的新型抗肿瘤药物。 [2] 本研究强调了三萜核心中的 A-氮杂环对于开发新型抗肿瘤剂的重要性，因此提高选择性特征的未来目标将在于改变氮杂三萜酸的羧基基团. [3] 因此，寡霉素 A 的二烯部分的修饰是开发基于其支架的新型抗肿瘤剂的有前景的策略。 [4] 这些结果表明化合物8f可作为一种有价值的骨架结构用于开发新型抗肿瘤药物。 [5] 它代表了进一步优化的有希望的线索和开发新型抗肿瘤药物的模板。 [6] 因此，化合物 MSN54 是开发新型抗肿瘤药物的有希望的候选者。 [7] 为了发现有效的新型抗肿瘤药物，根据已报道的 VEGFR-2 抑制剂的基本药效学特征，设计并合成了一系列带有 3-(4-甲氧基苯基)氮杂环丁烷部分的硫脲化合物。 [8] 由于食管癌预后不良，有必要发现新的抗肿瘤药物治疗食管癌。 [9] 在这篇综述中，我们证明了H2作为一种新型抗肿瘤剂的有效性和安全性，并表明其机制可能不仅涉及直接清除·OH，还涉及通过调节基因表达的其他间接生物防御机制。 [10] 因此，推测HO-1抑制剂可能成为一种新型抗肿瘤剂。 [11] 新型抗肿瘤剂的药物开发通常按阶段和癌症适应症划分。 [12] 由于食管癌预后不良，有必要发现新的抗肿瘤药物治疗食管癌。 [13] 因此，新型不饱和吡咯烷酮 p53-MDM2 抑制剂可以开发为新型抗肿瘤剂。 [14] 罗米地辛 (FK228) 和伏立诺他 (SAHA) 是美国食品和药物管理局批准的新型抗肿瘤药物组蛋白脱乙酰酶抑制剂 (HDACi)。 [15] 设计为热休克蛋白 90 (HSP90) C 末端抑制剂的 deguelin C 环截短支架的一系列 O 取代类似物作为抗人表皮生长因子受体 2 (HER2) 阳性乳腺癌的新型抗肿瘤剂进行了研究. [16] 本研究的目的是通过对 Ishikawa 和 HEC-1A 细胞的实验，探索使用 MRS5698 作为新型抗肿瘤剂的可能性。 [17] 尽管引入了新型抗肿瘤药物，如 dinutuximab、异维A酸、伊立替康或 I-131-间碘苄基胍，提高了存活率，但高危 NB 的情况仍然令人沮丧。 [18] 结论衍生物10是一种新型抗肿瘤药物，具有进一步临床应用治疗胃癌的潜力。 [19] 由于其有趣的生物学特征，(S)-1 是开发用于治疗乳腺癌的新型抗肿瘤药物的先导化合物。 [20] 我们的研究结果还表明，Rhein 具有用作治疗 NSCLC 的新型抗肿瘤药物的潜力。 [21] 这些结果表明EGLP具有更强的抗肿瘤活性和更低的毒性作用，具有成为新型抗肿瘤药物的潜力。 [22] 我们还建议通过抑制肿瘤相关血管生成，CGRP 抗体也可用作新型抗肿瘤剂。 [23] 因此，MnSbW-bpp 作为一种新化合物，具有对癌细胞的有效抑制作用，这表明 MnSbW-bpp 具有进一步评估新型抗肿瘤药物的潜在价值。 [24] 总体而言，目前的研究为发现一种新的抗 HCC 抗肿瘤药物提供了一种潜在的新方法。 [25] 研究工作的重点是破译耐药性的不同分子机制，这将促进开发能够克服这种化学耐药性的新型抗肿瘤药物。 [26] 在这里，我们展示了一种新型抗肿瘤剂 NCT 化合物的功效和生物学机制。 [27] 有机金属铼配合物由于其合适的特性，最近已被考虑用于开发新型抗肿瘤剂。 [28] 溶瘤病毒是新型抗肿瘤剂，能够选择性地复制和裂解肿瘤细胞，同时保留健康组织。 [29] 为寻找新型抗肿瘤药物，设计合成了一系列1H-苯并呋喃[3,2-c]吡唑衍生物4a-e。 [30] 结果表明，作为一种新型抗肿瘤剂，1G 表现出可接受的药代动力学特性，可用于进一步的体内药理学评估。 [31] 化疗耐药是卵巢癌患者最常见的死亡原因之一，寻找新的抗肿瘤药物是当务之急。 [32]
novel antitumor drug 新型抗肿瘤药物
Therefore, narciclasine might be a potential seed for a novel antitumor drug against malignant mesothelioma and other cancers in which hyperactivation and/or overexpression of YAP are observed. [1] The urea analogs of pretubulysin might represent a promising scaffold for the further development of novel antitumor drugs. [2] In this study, a novel antitumor drug cabozantinib (CZN) was estimated by a validated green reversed-phase high-performance thin-layer chromatography (RP-HPTLC) and normal-phase high-performance thin-layer chromatography (NP-HPTLC) techniques in the marketed tablets and capsules. [3] Conclusion These results indicate that at least for primary gastric cancer, statins and avasimibe are promising candidates as potential novel antitumor drugs that target the metabolism of isoprenoids and cholesterol of gastric tumors. [4] This research work reports new equilibrium solubility data for a novel weakly soluble tyrosine kinase inhibitor cabozantinib malate (CBZM) (a novel antitumor drug) in twelve different monosolvents (MS) of pharmaceutical importance including “water, methanol (MeOH), ethanol (EtOH), isopropanol (IPA), 1-butanol (1-BuOH), 2-butanol (2-BuOH), ethylene glycol (EG), propylene glycol (PG), polyethylene glycol-400 (PEG-400), ethyl acetate (EA), Transcutol-HP (THP) and dimethyl sulfoxide (DMSO)” within the temperature range “T = 298. [5] Our findings provide insights into the dynamics of integrin αvβ3 interactions with linear and cyclic RGD ligands and offer some new therapeutic approaches for the design and development of novel antitumor drugs. [6] Taken together, these results indicated that polyphyllin VII could be a novel antitumor drug for the treatment of CRC. [7] Background Colorectal cancer (CRC) is recognized as one of the most common malignancies with a high mortality rate worldwide, supporting the necessity for an effective novel antitumor drug to improve current therapy's effectiveness. [8] The simple design of zwitterionic prodrug micelles provides a new strategy for designing novel antitumor drug delivery systems with enhanced cellular uptake rates. [9] Due to their potent immune stimulation, tumor necrosis factor alpha (TNFα) variants with tumor-homing activity are attractive as novel antitumor drugs. [10] This initiated the increased demand for novel antitumor drugs that are active against untreatable tumors with fewer side effects, and with the greater therapeutic efficiency. [11] CONCLUSION Compound 5h might represent a promising scaffold for the further development of novel antitumor drugs. [12] This phenomenon may provide grounds for the development of novel antitumor drugs that are capable of selectively inducing oxidative stress in tumor cells. [13] Polydatin could be a potential compound to synthesize novel antitumor drugs. [14] This finding provides novel clues to exploring a novel antitumor drug for bile duct cancer. [15] The focus is mainly on the potential exploitation of the (DH)PIq scaffold in design and development of novel antitumor drugs. [16] Recently, drugs belonging to the biguanide class (including metformin) were reported to selectively inhibit CLIC1 activity in CSCs, impairing their viability and invasiveness, but sparing normal stem cells, thus representing potential novel antitumor drugs with a safe toxicological profile. [17] Spectroscopy experiments and cytotoxic assays against S-180 and Ehrlich cancer cell lines were performed and showed promising results as novel antitumor drugs. [18] BACKGROUND Ibrutinib is a novel antitumor drug that targets Bruton tyrosine kinase for treatment of chronic lymphocytic leukemia. [19]因此，narciclasine 可能是一种新的抗肿瘤药物的潜在种子，用于对抗恶性间皮瘤和其他癌症，其中观察到 YAP 的过度激活和/或过表达。 [1] 前微管溶素的尿素类似物可能代表一种有前途的支架，可用于进一步开发新型抗肿瘤药物。 [2] 在这项研究中，通过验证的绿色反相高效薄层色谱 (RP-HPTLC) 和正相高效薄层色谱 (NP-HPTLC) 技术估计了一种新型抗肿瘤药物卡博替尼 (CZN)在销售的片剂和胶囊中。 [3] 结论这些结果表明，至少对于原发性胃癌，他汀类药物和阿伐西贝作为靶向胃肿瘤异戊二烯和胆固醇代谢的潜在新型抗肿瘤药物是有希望的候选药物。 [4] 这项研究工作报告了一种新型弱溶性酪氨酸激酶抑制剂苹果酸卡博替尼 (CBZM)（一种新型抗肿瘤药物）在十二种不同的具有药学重要性的单溶剂 (MS) 中的新平衡溶解度数据，包括“水、甲醇 (MeOH)、乙醇 (EtOH) , 异丙醇 (IPA), 1-丁醇 (1-BuOH), 2-丁醇 (2-BuOH), 乙二醇 (EG), 丙二醇 (PG), 聚乙二醇-400 (PEG-400), 乙酸乙酯 (EA )、Transcutol-HP (THP) 和二甲基亚砜 (DMSO)”在温度范围“T = 298”内。 [5] 我们的研究结果为整合素 αvβ3 与线性和环状 RGD 配体相互作用的动力学提供了见解，并为设计和开发新型抗肿瘤药物提供了一些新的治疗方法。 [6] 总之，这些结果表明polyphyllin VII可能是一种治疗CRC的新型抗肿瘤药物。 [7] 背景 结直肠癌 (CRC) 被认为是全世界最常见的恶性肿瘤之一，死亡率很高，因此需要一种有效的新型抗肿瘤药物来提高当前治疗的有效性。 [8] 两性离子前药胶束的简单设计为设计具有增强细胞摄取率的新型抗肿瘤药物递送系统提供了新策略。 [9] 由于其强大的免疫刺激作用，具有肿瘤归巢活性的肿瘤坏死因子α (TNFα) 变体作为新型抗肿瘤药物具有吸引力。 [10] 这引发了对新型抗肿瘤药物的需求增加，这些药物对无法治疗的肿瘤具有活性，副作用更少，治疗效率更高。 [11] 结论 化合物 5h 可能代表一种有前途的支架，可用于进一步开发新型抗肿瘤药物。 [12] 这种现象可能为开发能够在肿瘤细胞中选择性诱导氧化应激的新型抗肿瘤药物提供基础。 [13] 虎杖苷可能是合成新型抗肿瘤药物的潜在化合物。 [14] 这一发现为探索治疗胆管癌的新型抗肿瘤药物提供了新线索。 [15] 重点主要是 (DH)PIq 支架在新型抗肿瘤药物设计和开发中的潜在开发。 [16] 最近，据报道属于双胍类的药物（包括二甲双胍）选择性地抑制 CSCs 中的 CLIC1 活性，削弱其活力和侵袭性，但不影响正常干细胞，因此代表了具有安全毒理学特征的潜在新型抗肿瘤药物。 [17] 进行了针对 S-180 和 Ehrlich 癌细胞系的光谱实验和细胞毒性测定，并显示出作为新型抗肿瘤药物的有希望的结果。 [18] 背景 依鲁替尼是一种靶向布鲁顿酪氨酸激酶的新型抗肿瘤药物，用于治疗慢性淋巴细胞白血病。 [19]
novel antitumor therapy 新型抗肿瘤疗法
Thus, an improved understanding of the regulatory mechanisms of COX-2 can facilitate the development of novel antitumor therapies. [1] Conclusion Our findings demonstrated that circLDB2 impeded non‐squamous NSCLC development and enhanced cisplatin sensitivity partially by acting as a ceRNA, highlighting circLDB2 as a promising candidate for the development of novel antitumor therapies. [2] These results indicate that CD73 has a dual effect on CD8+ T cells depending on whether they are subject to an antigenic or homeostatic stimulus, and thus, special attention should be given to these aspects when considering CD73 blockade in the design of novel antitumor therapies. [3] Despite considerable progress in early detection and treatment, there is still an unmet need for novel antitumor therapies, particularly in advanced colorectal cancer. [4] Along with the substantial progress in understanding of the role of tumor-derived vesicles in intercellular communication, novel antitumor therapy strategies based on vesicle inhibition in a tumor microenvironment are likely to appear very soon. [5] In this Perspectives Article, we focus on the following aspects: (1) the added value of IFN-I for enhancing the antitumor impact of standard anticancer treatments (chemotherapy and radiotherapy) and new therapeutic approaches, such as check point inhibitors and epigenetic drugs; (2) the role of IFN-I in the control of cancer stem cells growth and its possible implications for the development of novel antitumor therapies; and (3) the role of IFN-I in the development of cancer vaccines and the intriguing therapeutic possibilities offered by in situ delivery of ex vivo IFN-stimulated dendritic cells. [6] Taken together, overexpression of HOXA10 may be associated with poor prognosis in BC, and may serve as a novel antitumor therapy target for the treatment of this disease. [7] Although immune checkpoint blockade has recently emerged as a novel antitumor therapy, PDAC is less sensitive to immunotherapy due to small number of tumor-infiltrating T cells. [8]因此，更好地理解 COX-2 的调节机制可以促进新型抗肿瘤疗法的开发。 [1] 结论 我们的研究结果表明，circLDB2 通过充当 ceRNA 部分阻碍了非鳞状 NSCLC 的发展并增强了顺铂的敏感性，突出了 circLDB2 作为开发新型抗肿瘤疗法的有希望的候选者。 [2] 这些结果表明，CD73 对 CD8+ T 细胞具有双重作用，这取决于它们是否受到抗原或稳态刺激，因此，在设计新型抗肿瘤疗法时考虑 CD73 阻断时应特别注意这些方面。 [3] 尽管在早期检测和治疗方面取得了相当大的进展，但对于新型抗肿瘤疗法的需求仍未得到满足，特别是在晚期结直肠癌中。 [4] 随着对肿瘤源性囊泡在细胞间通讯中作用的理解取得实质性进展，基于肿瘤微环境中囊泡抑制的新型抗肿瘤治疗策略可能很快就会出现。 [5] 在这篇 Perspectives 文章中，我们重点关注以下几个方面：（1）IFN-I 在增强标准抗癌治疗（化疗和放疗）和新治疗方法（如检查点抑制剂和表观遗传药物）的抗肿瘤作用方面的附加价值； (2) IFN-I 在控制癌症干细胞生长中的作用及其对开发新型抗肿瘤疗法的可能意义； (3) IFN-I 在癌症疫苗开发中的作用以及体外 IFN 刺激的树突状细胞的原位递送提供的有趣的治疗可能性。 [6] 总之，HOXA10 的过表达可能与 BC 的不良预后相关，并可能作为治疗该疾病的新型抗肿瘤治疗靶点。 [7] 尽管免疫检查点阻断最近作为一种新型抗肿瘤疗法出现，但由于肿瘤浸润 T 细胞数量少，PDAC 对免疫疗法的敏感性较低。 [8]
novel antitumor strategy 新型抗肿瘤策略
These findings indicate that Cyr61 derived from ADSCs plays a critical role in promoting CRC progression via integrin αV β5 and provide a novel antitumor strategy by targeting Cyr61/αV β5. [1] Conclusions: This study provides strong evidence of the involvement of CD73 in the Warburg effect and indicates that it could be a novel antitumor strategy to target tumor metabolism in gastric cancer. [2] Conclusions: This study provides strong evidence of the involvement of PP2A in the Warburg effect and indicates that it could be a novel antitumor strategy to target tumor metabolism in gastric cancer. [3] The selective induction of tumor vascular thrombosis using truncated tissue factor (tTF) delivered via a target ligand is a promising novel antitumor strategy. [4] Given the multifaceted effects of VEGF-NRP interactions on tumor initiation and progression, the exploration of new chemical entities that selectively block these interactions has recently attracted considerable interest as a novel antitumor strategy. [5] For this reason, pharmacological targeting of Hsp90 has emerged as a novel antitumor strategy. [6]这些发现表明来自 ADSCs 的 Cyr61 通过整合素 αV β5 在促进 CRC 进展中起关键作用，并通过靶向 Cyr61/αV β5 提供了一种新的抗肿瘤策略。 [1] 结论：这项研究提供了 CD73 参与 Warburg 效应的有力证据，并表明它可能是一种靶向胃癌肿瘤代谢的新型抗肿瘤策略。 [2] 结论：本研究为 PP2A 参与 Warburg 效应提供了强有力的证据，并表明它可能是一种靶向胃癌肿瘤代谢的新型抗肿瘤策略。 [3] 使用通过靶配体递送的截短组织因子 (tTF) 选择性诱导肿瘤血管血栓形成是一种很有前途的新型抗肿瘤策略。 [4] 鉴于 VEGF-NRP 相互作用对肿瘤起始和进展的多方面影响，探索选择性阻断这些相互作用的新化学实体作为一种新的抗肿瘤策略最近引起了相当大的兴趣。 [5] nan [6]
novel antitumor mechanism 新型抗肿瘤机制
Overall, this work provides valuable leads and novel antitumor mechanisms for the treatment of the SAHA-resistant triple-negative breast cancers. [1] Together, our data revealed a novel antitumor mechanism of melatonin in modulating the immunosuppressive tumor microenvironment by suppressing the YAP/PD-L1 axis and suggest the therapeutic potential of melatonin for treating NSCLC. [2] These findings reveal a novel antitumor mechanism and a new combination regimen of the M1 oncolytic virus in TNBC, and highlight a need to bridge molecular diagnosis with virotherapy. [3] The current study revealed that the novel antitumor mechanism of metformin is mediated by regulation of mitochondrial E3 ubiquitin protein ligase 1 (MUL1) expression that negatively regulates AKT. [4]总体而言，这项工作为治疗 SAHA 耐药的三阴性乳腺癌提供了有价值的线索和新的抗肿瘤机制。 [1] 总之，我们的数据揭示了褪黑激素通过抑制 YAP/PD-L1 轴来调节免疫抑制性肿瘤微环境的新抗肿瘤机制，并提示褪黑激素治疗 NSCLC 的治疗潜力。 [2] 这些发现揭示了一种新的抗肿瘤机制和 M1 溶瘤病毒在 TNBC 中的新组合方案，并强调了将分子诊断与病毒疗法联系起来的必要性。 [3] 目前的研究表明，二甲双胍的新抗肿瘤机制是通过调节线粒体 E3 泛素蛋白连接酶 1 (MUL1) 的表达来介导的，该表达负调节 AKT。 [4]
novel antitumor treatment 新型抗肿瘤治疗
Further studies are needed to figure out their roles in tumor activity and provide insight for novel antitumor treatment development. [1] BACKGROUND Pancreatic cancer is a highly malignant tumor of the gastrointestinal system whose emerging resistance to chemotherapy has necessitated the development of novel antitumor treatments. [2] The present study highlights the great potential of biocompatible natural polysaccharide-based materials for biomedical applications, and provides a new strategy for reducing the toxicity and side effects associated with traditional chemotherapy, demonstrating a novel antitumor treatment paradigm with high-efficiency but with only minor side effects. [3]需要进一步的研究来弄清楚它们在肿瘤活性中的作用，并为新的抗肿瘤治疗开发提供见解。 [1] 背景技术胰腺癌是胃肠系统的高度恶性肿瘤，其对化学疗法的新出现的抗性使得开发新的抗肿瘤治疗成为必要。 [2] 本研究突出了生物相容性天然多糖基材料在生物医学应用中的巨大潜力，并为降低与传统化疗相关的毒副作用提供了新策略，展示了一种高效但副作用较小的新型抗肿瘤治疗范例效果。 [3]
novel antitumor factor
These data indicated that miR-495 might be a novel antitumor factor of GC and provide a new method for the treatment of GC. [1] Here, we described the molecular feature of LATS2 as a novel antitumor factor in liver cancer cells in vitro. [2]这些数据表明，miR-495可能是一种新型的GC抗肿瘤因子，为治疗GC提供了一种新的方法。 [1] 在这里，我们描述了 LATS2 作为体外肝癌细胞中一种新型抗肿瘤因子的分子特征。 [2]
novel antitumor therapeutic
Herein we describe the design and biological evaluation of a novel antitumor therapeutic platform that combines the most favorable properties of small-molecule drug conjugates (SMDCs) and antibody drug conjugates (ADCs). [1] The HCP5 antisense retroviral transcript also interacts with regulatory microRNA and immune and cellular checkpoints in cancers suggesting its potential as a drug target for novel antitumor therapeutics. [2]在此，我们描述了一种新型抗肿瘤治疗平台的设计和生物学评估，该平台结合了小分子药物偶联物 (SMDCs) 和抗体药物偶联物 (ADCs) 的最有利特性。 [1] HCP5 反义逆转录病毒转录物还与癌症中的调节性 microRNA 以及免疫和细胞检查点相互作用，这表明它具有作为新型抗肿瘤治疗药物靶点的潜力。 [2]
novel antitumor effect
e16511Background: Inactivated Sendai virus particles (hemagglutinating virus of Japan envelope (HVJ-E)) have a novel antitumor effect: HVJ-E fused to prostate cancer cells via cell surface receptor. [1] Taken together, our findings reveal that frugoside exhibits a novel antitumor effect based on a ROS-mediated cell death in melanoma cells, which may have therapeutic implications. [2]e16511背景：灭活的仙台病毒颗粒（日本包膜血凝病毒（HVJ-E））具有新的抗肿瘤作用：HVJ-E通过细胞表面受体与前列腺癌细胞融合。 [1] 综上所述，我们的研究结果表明，frugoside 表现出基于 ROS 介导的黑色素瘤细胞死亡的新型抗肿瘤作用，这可能具有治疗意义。 [2]
novel antitumor candidate
In an attempt to develop novel antitumor candidates, a series of coumarin sulfonamides and amides derivatives were designed and synthetized. [1] Herein, our study provides a novel antitumor candidate and approach for treating AML. [2]为了开发新的抗肿瘤候选物，设计和合成了一系列香豆素磺酰胺和酰胺衍生物。 [1] 在此，我们的研究提供了一种新的抗肿瘤候选药物和治疗 AML 的方法。 [2]